Physician profile
Frederick Taylor
NPI 1558527192
$4,709.09
in general payments reported to CMS, 2019-2025
28 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $332 · 2021: $384 · 2022: $886 · 2023: $157 · 2024: $1,003 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $877.81 | 2019-2025 | Ams 700 |
| Teleflex LLC | $686.31 | 2020-2023 | Urolift |
| Sumitomo Pharma America, INC. | $651.15 | 2023-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $297.53 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $292.66 | 2019-2024 | Xiaflex, Aveed |
| Neotract INC. | $240.09 | 2019-2020 | |
| Astellas Pharma US INC | $223.96 | 2019-2021 | |
| Endo USA, INC. | $204.05 | 2024-2025 | Xiaflex, Aveed |
| Antares Pharma, INC. | $190.07 | 2019-2024 | Xyosted |
| Ferring Pharmaceuticals INC. | $186.84 | 2019-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $182.47 | 2024-2025 | Prolaris |
| Abbvie INC. | $122.72 | 2019-2025 | |
| Myovant Sciences INC. | $72.86 | 2021-2022 | |
| Urovant Sciences INC | $64.37 | 2022 | |
| Medtronic USA, INC. | $64.14 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $46.77 | 2023-2025 | |
| Rochester Medical Corporation | $45.00 | 2021 | |
| Pfizer INC. | $44.68 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.95 | 2024-2025 | Keytruda, Welireg |
| Urogen Pharma, INC. | $41.72 | 2023-2024 | Jelmyto |
| C. R. Bard, INC. & Subsidiaries | $30.00 | 2019 | |
| Dendreon Pharmaceuticals LLC | $23.90 | 2024 | Provenge |
| Vertex Pharmaceuticals Incorporated | $19.84 | 2024 | |
| Blue Earth Diagnostics | $19.07 | 2023 | |
| Halozyme INC | $14.39 | 2023 | |
| Janssen Biotech, INC. | $11.41 | 2019 | |
| Clarus Therapeutics INC. | $11.33 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$657.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.